Year |
Citation |
Score |
2019 |
Nackiewicz D, Dan M, Speck M, Chow SZ, Chen YC, Pospisilik JA, Verchere CB, Ehses JA. Islet Macrophages Shift to a Reparative State following Pancreatic Beta-Cell Death and Are a Major Source of Islet Insulin-like Growth Factor-1. Iscience. 23: 100775. PMID 31962237 DOI: 10.1016/J.Isci.2019.100775 |
0.423 |
|
2018 |
Lu TT, Heyne S, Dror E, Casas E, Leonhardt L, Boenke T, Yang CH, Sagar, Arrigoni L, Dalgaard K, Teperino R, Enders L, Selvaraj M, Ruf M, Raja SJ, ... ... Pospisilik JA, et al. The Polycomb-Dependent Epigenome Controls β Cell Dysfunction, Dedifferentiation, and Diabetes. Cell Metabolism. PMID 29754954 DOI: 10.1016/J.Cmet.2018.04.013 |
0.599 |
|
2010 |
Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, Schraenen A, Lemaire K, Debray S, Van Lommel L, Pospisilik JA, Tschopp O, Schultze SM, Malipiero U, Esterbauer H, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia. 53: 1795-806. PMID 20407745 DOI: 10.1007/S00125-010-1747-3 |
0.49 |
|
2007 |
Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, Ebersberger I, Nakashima T, Sarao R, Neely G, Esterbauer H, Kozlov A, Kahn CR, Kroemer G, Rustin P, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 131: 476-91. PMID 17981116 DOI: 10.1016/J.Cell.2007.08.047 |
0.445 |
|
2007 |
Piteau S, Olver A, Kim SJ, Winter K, Pospisilik JA, Lynn F, Manhart S, Demuth HU, Speck M, Pederson RA, McIntosh CH. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochemical and Biophysical Research Communications. 362: 1007-12. PMID 17803965 DOI: 10.1016/J.Bbrc.2007.08.115 |
0.709 |
|
2007 |
Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 56: 2356-70. PMID 17579207 DOI: 10.2337/Db06-1650 |
0.436 |
|
2006 |
McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. The International Journal of Biochemistry & Cell Biology. 38: 860-72. PMID 16442340 DOI: 10.1016/J.Biocel.2005.12.013 |
0.715 |
|
2005 |
McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regulatory Peptides. 128: 159-65. PMID 15780435 DOI: 10.1016/J.Regpep.2004.06.001 |
0.659 |
|
2004 |
Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, Brownsey R, Wambolt R, Allard M, Rodrigues B. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes. 53: 1790-7. PMID 15220203 DOI: 10.2337/Diabetes.53.7.1790 |
0.463 |
|
2003 |
Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA, McIntosh CH. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology. 144: 4433-45. PMID 12960055 DOI: 10.1210/En.2002-0068 |
0.661 |
|
2003 |
Pospisilik JA, Ehses JA, Doty T, McIntosh CH, Demuth HU, Pederson RA. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Advances in Experimental Medicine and Biology. 524: 281-91. PMID 12675250 DOI: 10.1007/0-306-47920-6_34 |
0.653 |
|
2003 |
Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 52: 741-50. PMID 12606516 DOI: 10.2337/Diabetes.52.3.741 |
0.755 |
|
2003 |
Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, Pederson RA. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. American Journal of Physiology. Endocrinology and Metabolism. 284: E931-9. PMID 12540373 DOI: 10.1152/Ajpendo.00270.2002 |
0.726 |
|
2003 |
Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, Pederson RA. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 91-3. PMID 12475913 DOI: 10.1096/Fj.02-0243Fje |
0.744 |
|
2002 |
Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes. 51: 2677-83. PMID 12196458 DOI: 10.2337/Diabetes.51.9.2677 |
0.735 |
|
2002 |
Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 51: 943-50. PMID 11916911 DOI: 10.2337/Diabetes.51.4.943 |
0.731 |
|
2001 |
Pospisilik JA, Hinke SA, Pederson RA, Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CH, Demuth H. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regulatory Peptides. 96: 133-41. PMID 11111019 DOI: 10.1016/S0167-0115(00)00170-1 |
0.633 |
|
2000 |
Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kühn-Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CH. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. The Journal of Biological Chemistry. 275: 3827-34. PMID 10660533 DOI: 10.1074/Jbc.275.6.3827 |
0.577 |
|
Show low-probability matches. |